Retatrutide (formerly known as M25) is an investigational peptide being developed for the treatment of obesity and metabolic diseases. It belongs to a class of peptides known as dual or triple agonists that target multiple hormonal pathways involved in regulating metabolism, appetite, and energy balance. Specifically, Retatrutide is a multireceptor agonist that combines the effects of GLP-1, GIP, and Glucagon receptors, all of which are critical to metabolic processes. Retatrutide is being studied for its potential to provide more efficient weight loss and improve metabolic health by targeting multiple receptors involved in appetite suppression, insulin sensitivity, and fat loss.